Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders

A Del Grosso, G Parlanti, R Mezzena… - Advanced Drug Delivery …, 2022 - Elsevier
Lysosomal storage disorders (LSDs) are a vast group of more than 50 clinically identified
metabolic diseases. They are singly rare, but they affect collectively 1 on 5,000 live births …

What's new and what's next for gene therapy in Pompe disease?

AL Roger, R Sethi, ML Huston, E Scarrow… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Pompe disease is an autosomal recessive disorder caused by a deficiency of
acid-α-glucosidase (GAA), an enzyme responsible for hydrolyzing lysosomal glycogen. A …

Respiratory dysfunction in a mouse model of spinocerebellar ataxia type 7

AF Fusco, LA Pucci, PM Switonski… - Disease models & …, 2021 - journals.biologists.com
ABSTRACT Spinocerebellar ataxia type 7 (SCA7) is an autosomal-dominant
neurodegenerative disorder caused by a CAG repeat expansion in the coding region of the …

[HTML][HTML] Pathophysiology of Lysosomes in a Nutshell

C Isidoro - International Journal of Molecular Sciences, 2023 - mdpi.com
Lysosomes are acidic organelles present in all nucleated mammalian cells. They represent
the final destination for the degradation of extracellular and intracellular material therein …

GAA deficiency disrupts distal airway cells in Pompe disease

L El Haddad, E Lai, PKL Murthy… - … of Physiology-Lung …, 2023 - journals.physiology.org
Pompe disease is an autosomal recessive glycogen storage disease caused by mutations in
the gene that encodes acid alpha-glucosidase (GAA)—an enzyme responsible for …

[HTML][HTML] Infantile Pompe disease with intrauterine onset: a case report and literature review

H Xi, X Li, L Ma, X Yin, P Yang, L Zhang - Italian Journal of Pediatrics, 2022 - Springer
Background Pompe disease is a rare autosomal recessive disease. Acid alpha−
glucosidase (GAA) deficiency leads to glycogen storage in lysosomes, causing skeletal …

Diaphragm weakness in late-onset Pompe disease: A complex interplay between lower motor neuron and muscle fibre degeneration

MO Santos, S Domingues, CF de Campos… - Journal of the …, 2024 - Elsevier
Abstract Background Late-onset Pompe disease (LOPD) patients may still need ventilation
support at some point of their disease course, despite regular recombinant human …

[HTML][HTML] 庞贝病神经系统损伤的研究进展

张文超, 毛莹莹, 陈倩 - Chinese Journal of Contemporary …, 2023 - ncbi.nlm.nih.gov
庞贝病( Pompe disease) 亦称糖原贮积病Ⅱ 型, 是常染色体隐性遗传的罕见病,
随着酶替代疗法的应用, 越来越多的庞贝病患者可存活至成年, 以往未曾观察到的神经系统 …

Airway abnormalities and pulmonary complications in long‐term treated late‐onset Pompe disease: Diagnostic and interventional by flexible bronchoscopy

TH Wang, WJ Soong, DM Niu, YL Chu… - Pediatric …, 2022 - Wiley Online Library
This study evaluates the whole airway abnormalities of long‐term treated late‐onset Pompe
disease (LOPD) patients, with interventions using the flexible bronchoscope (FB). As a …

High-specific activity variants of recombinant human α-glucosidase for the treatment of Pompe disease

A Lakshminarasimhan - Medical Hypotheses, 2023 - Elsevier
Pompe disease is a rare genetic disorder with an estimated incidence of 1 in 40,000
individuals worldwide. This autosomal recessive disease is a neuromuscular disorder …